Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
PLoS One. 2010 Sep 16;5(9):e12747. doi: 10.1371/journal.pone.0012747.
Indian guidelines recommend routine referral for HIV testing of all tuberculosis (TB) patients in the nine states with the highest HIV prevalence, and selective referral for testing elsewhere. We assessed the clinical impact and cost-effectiveness of alternative HIV testing referral strategies among TB patients in India.
We utilized a computer model of HIV and TB disease to project outcomes for patients with active TB in India. We compared life expectancy, cost, and cost-effectiveness for three HIV testing referral strategies: 1) selective referral for HIV testing of those with increased HIV risk, 2) routine referral of patients in the nine highest HIV prevalence states with selective referral elsewhere (current standard), and 3) routine referral of all patients for HIV testing. TB-related data were from the World Health Organization. HIV prevalence among TB patients was 9.0% in the highest prevalence states, 2.9% in the other states, and 4.9% overall. The selective referral strategy, beginning from age 33.50 years, had a projected discounted life expectancy of 16.88 years and a mean lifetime HIV/TB treatment cost of US$100. The current standard increased mean life expectancy to 16.90 years with additional per-person cost of US$10; the incremental cost-effectiveness ratio was US$650/year of life saved (YLS) compared to selective referral. Routine referral of all patients for HIV testing increased life expectancy to 16.91 years, with an incremental cost-effectiveness ratio of US$730/YLS compared to the current standard. For HIV-infected patients cured of TB, receiving antiretroviral therapy increased survival from 4.71 to 13.87 years. Results were most sensitive to the HIV prevalence and the cost of second-line antiretroviral therapy.
Referral of all patients with active TB in India for HIV testing will be both effective and cost-effective. While effective implementation of this strategy would require investment, routine, voluntary HIV testing of TB patients in India should be recommended.
印度指南建议在 HIV 流行率最高的九个邦对所有结核病 (TB) 患者进行常规 HIV 检测,并选择性地对其他地区的患者进行检测。我们评估了在印度结核病患者中替代 HIV 检测转诊策略的临床影响和成本效益。
我们利用 HIV 和结核病疾病的计算机模型来预测印度活动性结核病患者的结局。我们比较了三种 HIV 检测转诊策略的预期寿命、成本和成本效益:1)对 HIV 风险增加的患者进行选择性 HIV 检测转诊,2)对 HIV 流行率最高的九个邦的患者进行常规转诊,并对其他地区进行选择性转诊(当前标准),3)对所有患者进行常规 HIV 检测转诊。结核病相关数据来自世界卫生组织。在 HIV 流行率最高的邦,结核病患者中的 HIV 流行率为 9.0%,其他邦为 2.9%,总体为 4.9%。从 33.50 岁开始的选择性转诊策略预计有 16.88 年的贴现预期寿命和 100 美元的终身 HIV/TB 治疗费用。当前标准使平均预期寿命增加到 16.90 年,每人增加 10 美元的费用;增量成本效益比为每挽救一年生命 650 美元(YLS),与选择性转诊相比。对所有患者进行常规 HIV 检测转诊将预期寿命提高到 16.91 年,与当前标准相比,增量成本效益比为每挽救一年生命 730 美元。对于接受结核病治疗后 HIV 感染已治愈的患者,接受抗逆转录病毒治疗可将其生存时间从 4.71 年延长至 13.87 年。结果对 HIV 流行率和二线抗逆转录病毒治疗的成本最为敏感。
在印度,对所有活动性结核病患者进行 HIV 检测既有效又具有成本效益。虽然实施这一策略需要投资,但印度应推荐对结核病患者进行常规、自愿的 HIV 检测。